These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. One-year mortality in patients with bone and soft tissue sarcomas as an indicator of delay in presentation. Nandra R, Hwang N, Matharu GS, Reddy K, Grimer R. Ann R Coll Surg Engl; 2015 Sep; 97(6):425-33. PubMed ID: 26274756 [Abstract] [Full Text] [Related]
6. Down-regulated E-cadherin expression is associated with poor five-year overall survival in bone and soft tissue sarcoma: results of a meta-analysis. Wang N, He YL, Pang LJ, Zou H, Liu CX, Zhao J, Hu JM, Zhang WJ, Qi Y, Li F. PLoS One; 2015 Sep; 10(3):e0121448. PubMed ID: 25822802 [Abstract] [Full Text] [Related]
8. The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta-analysis. Wang F, Yu T, Ma C, Zhang H, Zhang Z. FEBS Open Bio; 2019 Oct; 9(10):1744-1755. PubMed ID: 31376222 [Abstract] [Full Text] [Related]
17. The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis. Qiu L, Xu Y, Xu H, Yu B. BMC Cancer; 2022 Jun 21; 22(1):681. PubMed ID: 35729596 [Abstract] [Full Text] [Related]
19. Grb2-associated binding protein-1 as a biomarker in bone and soft tissue sarcomas. Al-Husseinawi E, Bui MM, Ahmed AA. Pathology; 2019 Oct 21; 51(6):610-614. PubMed ID: 31443923 [Abstract] [Full Text] [Related]